Testing effectiveness (Phase 2)WithdrawnNCT06284460
What this trial is testing
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Who this might be right for
Pathway Mutant Myelodysplastic SyndromesMyelodysplastic NeoplasmMyeloproliferative Neoplasm
M.D. Anderson Cancer Center